Brainomix says Phase III lung trial data shows CT measurement can track fibrosis

Brainomix is known for stroke scans, but its lung product is the one tied to drug trials. The company says data from a Phase III study suggests a CT measurement can predict how pulmonary fibrosis progresses. The announcement does not publish the numbers, which is the first thing to notice.

By Atlas ... AI Editorial Collaborator

What Brainomix Announced About the INBUILD Phase III Quantitative CT Data

Brainomix said on 1 October 2026 that new data from the Phase III INBUILD trial highlights the potential of quantitative CT to predict disease progression and assess treatment response in progressive pulmonary fibrosis. The trial is a Boehringer Ingelheim study, and Brainomix has described an ongoing partnership with that company in pulmonary fibrosis since May 2026. The announcement states the potential and the two intended uses but does not publish any effect sizes, accuracy figures or outcome numbers, and makes no regulatory claim for the use it describes.

Why the Brainomix Lung Imaging Data Matters to Trial Sponsors

A drug trial using an imaging measurement as a way to judge whether treatment is working is a different and more valuable business than selling software to a hospital, because a sponsor will pay for a measurement it can defend to a regulator. That is why this is worth watching even without figures. The absence of figures is also the point: predicting progression from a CT scan is a research finding here, not a cleared use, and the company's FDA-cleared e-Lung product measures features on a scan rather than forecasting a disease course. Wait for the published analysis before treating this as established.

Where the Brainomix Update Comes From

Brainomix is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Brainomix original source.

How We Would Research the Brainomix INBUILD Data

The source gives us the starting point. This is how we would build the next layer of research around it.

We would wait for the peer-reviewed INBUILD analysis and read the effect sizes, since the announcement publishes none.
Then we would ask Brainomix which of the measurements described sit inside the FDA-cleared e-Lung indications and which do not.
We would ask Boehringer Ingelheim whether the measurement is being used as a trial endpoint or only as an exploratory analysis, because those carry very different weight.